Clene (CLNN) Competitors $3.22 +0.04 (+1.26%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$3.23 +0.01 (+0.31%) As of 03/28/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLNN vs. EPRX, TIL, SGMT, MCRB, MGNX, VIRI, FTLF, VXRT, EDIT, and ELUTShould you be buying Clene stock or one of its competitors? The main competitors of Clene include Eupraxia Pharmaceuticals (EPRX), Instil Bio (TIL), Sagimet Biosciences (SGMT), Seres Therapeutics (MCRB), MacroGenics (MGNX), Virios Therapeutics (VIRI), FitLife Brands (FTLF), Vaxart (VXRT), Editas Medicine (EDIT), and Elutia (ELUT). These companies are all part of the "pharmaceutical products" industry. Clene vs. Eupraxia Pharmaceuticals Instil Bio Sagimet Biosciences Seres Therapeutics MacroGenics Virios Therapeutics FitLife Brands Vaxart Editas Medicine Elutia Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability. Do analysts prefer EPRX or CLNN? Eupraxia Pharmaceuticals presently has a consensus target price of $10.50, indicating a potential upside of 215.41%. Clene has a consensus target price of $55.25, indicating a potential upside of 1,615.84%. Given Clene's higher possible upside, analysts plainly believe Clene is more favorable than Eupraxia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Clene 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has higher valuation and earnings, EPRX or CLNN? Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Clene. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEupraxia PharmaceuticalsN/AN/A-$28.22M-$0.76-4.38Clene$342K78.39-$49.50M-$5.75-0.56 Does the MarketBeat Community favor EPRX or CLNN? Clene received 75 more outperform votes than Eupraxia Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Eupraxia Pharmaceuticals an outperform vote while only 80.61% of users gave Clene an outperform vote. CompanyUnderperformOutperformEupraxia PharmaceuticalsOutperform Votes4100.00% Underperform VotesNo VotesCleneOutperform Votes7980.61% Underperform Votes1919.39% Do institutionals and insiders believe in EPRX or CLNN? 23.3% of Clene shares are held by institutional investors. 25.1% of Clene shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to EPRX or CLNN? In the previous week, Clene had 30 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 32 mentions for Clene and 2 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 0.63 beat Clene's score of 0.12 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Clene 1 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is EPRX or CLNN more profitable? Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Clene's net margin of -8,556.77%. Eupraxia Pharmaceuticals' return on equity of -219.64% beat Clene's return on equity.Company Net Margins Return on Equity Return on Assets Eupraxia PharmaceuticalsN/A -219.64% -96.00% Clene -8,556.77%-1,106.30%-85.11% SummaryClene beats Eupraxia Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Remove Ads Get Clene News Delivered to You Automatically Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLNN vs. The Competition Export to ExcelMetricClenePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.81M$6.90B$5.63B$7.84BDividend YieldN/A2.77%5.33%4.01%P/E Ratio-0.617.2623.6018.74Price / Sales78.39218.62388.2390.77Price / CashN/A65.6738.1734.64Price / Book1.546.386.894.23Net Income-$49.50M$142.34M$3.20B$247.47M7 Day Performance-22.22%-5.15%-3.06%-2.29%1 Month Performance-28.44%-7.55%1.52%-5.81%1 Year Performance-62.15%-11.06%9.37%-0.96% Clene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLNNClene3.4724 of 5 stars$3.22+1.3%$55.25+1,615.8%-62.2%$27.65M$342,000.00-0.61100Earnings ReportShort Interest ↓Analyst RevisionNews CoverageGap UpEPRXEupraxia Pharmaceuticals2.8133 of 5 stars$3.65-4.6%$10.50+188.1%N/A$129.93MN/A-5.0629Positive NewsTILInstil Bio3.1735 of 5 stars$19.51+9.1%$114.00+484.3%+67.4%$127.32MN/A-1.69410Positive NewsSGMTSagimet Biosciences2.8777 of 5 stars$4.13+3.5%$23.00+456.9%-31.5%$126.69M$2M-2.898Short Interest ↓Positive NewsMCRBSeres Therapeutics3.4664 of 5 stars$0.71+0.3%$4.00+460.9%-6.9%$124.34M$126.33M-3.10330Analyst RevisionPositive NewsMGNXMacroGenics3.886 of 5 stars$1.96-2.0%$7.63+289.0%-91.4%$123.02M$148.34M-1.24430Analyst ForecastAnalyst RevisionVIRIVirios Therapeutics0.3922 of 5 stars$6.33-7.3%$3.00-52.6%+1,077.2%$121.90MN/A-23.445Gap UpFTLFFitLife Brands4.475 of 5 stars$13.23-1.9%$20.50+55.0%+5.9%$121.85M$62.76M15.6620Earnings ReportShort Interest ↓Analyst RevisionVXRTVaxart2.1978 of 5 stars$0.51-0.7%$4.00+680.3%-67.6%$116.61M$28.70M-1.25120Analyst ForecastAnalyst RevisionNews CoverageEDITEditas Medicine4.1682 of 5 stars$1.39+6.1%$6.83+391.6%-83.2%$115.34M$32.31M-0.54230Analyst RevisionPositive NewsELUTElutia3.9271 of 5 stars$2.81-3.8%$9.00+220.3%-16.2%$114.47M$24.38M-1.08180Short Interest ↓News Coverage Remove Ads Related Companies and Tools Related Companies EPRX Competitors TIL Competitors SGMT Competitors MCRB Competitors MGNX Competitors VIRI Competitors FTLF Competitors VXRT Competitors EDIT Competitors ELUT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLNN) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CLNN Stock Free CLNN Stock Alerts